Disclosure Of Earnings Per Share [Text Block]

Xbrane Biopharma - Filing #679209

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Disclosure of earnings per share [text block]
Earnings per share [text block]
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share from continuing operations
1,122.00
659.00
Basic earnings (loss) per share
1,352.00
675.00
Diluted earnings per share [abstract]
Diluted earnings (loss) per share from continuing operations
1,122.00
659.00
Diluted earnings (loss) per share
1,352.00
675.00
Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]
Weighted average number of ordinary shares used in calculating basic earnings per share
28 705 554 xbrli:shares
25 569 950 xbrli:shares
Weighted average number of ordinary shares used in calculating diluted earnings per share
28 705 554 xbrli:shares
25 569 950 xbrli:shares
Adjustments to reconcile profit (loss) to numerator used in calculating earnings per share [abstract]
Profit (loss), attributable to owners of parent
388 172 SEK
172 513 SEK
Disclosure of depositary receipts [text block]
Disclosure of depositary receipts [abstract]
Disclosure of depositary receipts [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.